Related Experiment Video
Updated: Dec 27, 2025
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.6K
Outcomes after stereotactic radiosurgery for CNS lymphoma
Joshua D Palmer1, Deepak Bhamidipati2, Gaurav Shukla2
1Department of Radiation Oncology, The James Cancer Hospital and Solove Research Institute, Ohio State University Wexner Medical Center, 460 W 10th Avenue, Columbus, OH, 43210, USA. Joshua.palmer@osumc.edu.
Journal of Neuro-Oncology
|February 29, 2020
Summary
Stereotactic radiosurgery (SRS) shows promise for treating refractory central nervous system (CNS) lymphoma, offering good local control with acceptable tolerance. Further prospective trials are needed to confirm its efficacy in CNS lymphoma patients.
Area of Science:
- Neurology
- Radiation Oncology
- Oncology
Background:
- Standard treatment for CNS lymphoma involves high-dose methotrexate and whole-brain radiation, which carries a risk of neurotoxicity.
- Stereotactic radiosurgery (SRS) is an alternative for refractory disease.
- Literature review on SRS for CNS lymphoma was conducted.
Purpose of the Study:
- To evaluate the efficacy and safety of SRS for CNS lymphoma.
- To assess local control and survival outcomes.
- To compare SRS with existing treatment modalities.
Main Methods:
- Retrospective review of six patients treated with SRS for refractory CNS lymphoma.
- SRS delivered in 1-3 fractions at 21 or 24 Gy.
- Systematic literature search of PubMed, SCOPUS, and Cochrane Library for SRS in CNS lymphoma.
Main Results:
- Six patients with eleven lesions were treated with SRS.
- Median follow-up was 15.6 months; median time to progression was 12.7 months.
- Complete response in 69% of lesions; local recurrence in 6% of patients. Treatment was well tolerated.
Conclusions:
- SRS may offer favorable local control for refractory CNS lymphomas.
- A prospective trial is recommended to validate SRS efficacy.
- SRS presents a viable option for managing CNS lymphoma with reduced toxicity.
